1. Cancer facts & figures 2014. Atlanta, GA: American Cancer Society; 2012. p. 12.
2. Haas GP, Delongchamps NB, Jones RF, Chandan V, Serio AM, Vickers AJ, Jumbelic M, Threatte G, Korets R, Lilja H, de la Roza G. Needle biopsies on autopsy prostates: sensitivity of cancer detection based on true prevalence. J Natl Cancer Inst. 2007;99(19):1484–9.
3. Applewhite J, Matlaga B, McCullough D. Results of the 6-region prostate biopsy method: the repeat biopsy population. J Urol. 2002;168(2):500–3.
4. Feleppa EJ, Ketterling JA, Kalisz A, Urban S, Schiff PB, Ennis RD, Wuu CS, Porter CR, Fair WR, Gillespie JW. Application of spectrum analysis and neural-network classification to imaging for targeting and monitoring treatment of prostate cancer. In: Schneider S, Levy M, McAvoy B, editors. Proceedings of the 2001 ultrasonics symposium. Piscataway: IEEE; 2002. p. 1269–72.
5. Feliciano J, Teper E, Ferrandino M, Macchia RJ, Blank W, Grunberger I, Colon I. The incidence of fluoroquinoline-resistant infections after prostate biopsy—are fluoroquinolines still effective prophylaxis? J Urol. 2008;179:952–5.